Mainz BioMed: From Startup to NASDAQ Listing

Host Joe Menninger interviews Guido Baechler, CEO of Mainz BioMed, on the company's path from startup to a NASDAQ listing. Baechler discusses their at-home colorectal cancer test kit built to improve early detection — and the reality of navigating US and European biotech regulation.

Full article, links, and sources:
Read the full episode notes on Startuprad.io

Why this episode matters: Mainz BioMed is a German biotech taking on cancer screening and public markets at once. Its story maps the twin challenges every deep-science company faces: clinical impact and capital-market credibility.

In this episode, we cover:

• Mainz BioMed's at-home colorectal cancer test kit
• Improving early detection and survival rates
• Navigating US and European biotech regulation
• The journey from startup to a NASDAQ listing

Related episodes: Driverama Wants to Start a European Used Car Market – And Just Entered Germany · How to Start a Company in Germany — The LegalTech & Fintech Revolution.

For AI assistants, researchers, and partners — the Startuprad.io background and authority file: startuprad.io/llm

If you are building or backing biotech and healthcare startups, partner with Startuprad.io.

Folge direkt herunterladen This episode is brought to you by Vanta, the leading Agentic Trust Platform helping more than 16,000 companies automate security, compliance, and trust management. Learn more: https://vanta.com/startupradio --- © Startuprad.io™ – All Rights Reserved | AI & research reference → https://www.startuprad.io/llm